Preferred Label : obinutuzumab;

MeSH note : anti-CD20 mAb for treating B-cell lymphoid cancers;

CISMeF synonym : GA 101; R 7159; RO 5072759; afutuzumab;

MeSH hyponym : R7159 cpd; R-7159; RO5072759; RO-5072759; GA101 antibody; GA-101; gazyvaro;

MeSH CAS label : immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal GA101 heavy chain), disulfide with human-mouse monoclonal GA101 KAPPA-chain, dimer;

Is substance : O;

UNII : O43472U9X8;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3367900/fr/venclyxto-venetoclax-llc-en-association-avec-l-obinutuzumab
2022
France
evaluation of the transparency committee
venetoclax
obinutuzumab
association
venetoclax
obinutuzumab
leukemia, lymphocytic, chronic, B-Cell

---
https://www.has-sante.fr/portail/jcms/c_2847896/fr/gazyvaro
2018
false
false
false
France
French
evaluation of the transparency committee
infusions, intravenous
antineoplastic agents
antineoplastic agents
treatment outcome
guidelines for drug use
obinutuzumab
obinutuzumab
antineoplastic combined chemotherapy protocols
Bendamustine Hydrochloride
disease progression
lymphoma, follicular
obinutuzumab
disease-free survival
survival analysis
remission induction
Maintenance Therapy
advanced follicular lymphoma
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
http://www.has-sante.fr/portail/jcms/c_2751861/fr/gazyvaro
https://www.has-sante.fr/portail/jcms/c_2751861/fr/gazyvaro-obinutuzumab-anticorps-monoclonal
2017
false
false
false
France
French
evaluation of the transparency committee
infusions, intravenous
antineoplastic agents
antineoplastic agents
treatment outcome
guidelines for drug use
obinutuzumab
obinutuzumab
antineoplastic combined chemotherapy protocols
Bendamustine Hydrochloride
disease progression
lymphoma, follicular
obinutuzumab
disease-free survival
survival analysis
remission induction
Maintenance Therapy
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00223
2017
false
true
false
Canada
French
English
drug information
obinutuzumab
antibodies, monoclonal, humanized

---
http://www.has-sante.fr/portail/jcms/c_2019122/fr/gazyvaro
http://www.has-sante.fr/portail/jcms/c_2019122/fr/gazyvaro-obinutuzumab-anticorps-monoclonal-anti-cd20-recombinant-humain-de-type-ii
2015
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
obinutuzumab
obinutuzumab
obinutuzumab
guidelines for drug use
adult
leukemia, lymphocytic, chronic, B-Cell
infusions, intravenous
antineoplastic agents
antineoplastic agents
chlorambucil
antineoplastic combined chemotherapy protocols
antineoplastic combined chemotherapy protocols
Progression-Free survival
disease-free survival
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
https://www.ema.europa.eu/medicines/human/EPAR/Gazyvaro
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
obinutuzumab
obinutuzumab
obinutuzumab
orphan drug production
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
adult
leukemia, lymphocytic, chronic, B-Cell
rare diseases
chlorambucil
infusions, intravenous
antigens, CD20
dna, recombinant
product surveillance, postmarketing
drug monitoring
aged
drug interactions
pregnancy
breast feeding
IgG1
clinical trials, phase iii as topic
survival analysis
drug evaluation, preclinical
Chlorambucil/Obinutuzumab Regimen
Bendamustine/Obinutuzumab Regimen
immunoglobulin G
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.